Processa Pharmaceuticals, Inc.
PCSA
$0.2294
-$0.0059-2.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.02M | 1.14M | 1.35M | 1.27M | 1.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.73M | 3.42M | 3.08M | 2.81M | 2.47M |
| Operating Income | -2.73M | -3.42M | -3.08M | -2.81M | -2.47M |
| Income Before Tax | -2.73M | -3.38M | -3.01M | -2.73M | -2.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.73M | -3.38M | -3.01M | -2.73M | -2.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.73M | -3.38M | -3.01M | -2.73M | -2.40M |
| EBIT | -2.73M | -3.42M | -3.08M | -2.81M | -2.47M |
| EBITDA | -2.73M | -3.42M | -3.08M | -2.81M | -2.47M |
| EPS Basic | -0.78 | -1.03 | -1.01 | -1.11 | -1.71 |
| Normalized Basic EPS | -0.49 | -0.65 | -0.63 | -0.69 | -1.07 |
| EPS Diluted | -0.78 | -1.03 | -1.01 | -1.11 | -1.71 |
| Normalized Diluted EPS | -0.49 | -0.65 | -0.63 | -0.69 | -1.07 |
| Average Basic Shares Outstanding | 3.51M | 3.28M | 2.98M | 2.47M | 1.41M |
| Average Diluted Shares Outstanding | 3.51M | 3.28M | 2.98M | 2.47M | 1.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |